Edition:
India

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

19.25USD
9:40pm IST
Change (% chg)

$0.30 (+1.58%)
Prev Close
$18.95
Open
$18.91
Day's High
$19.39
Day's Low
$18.91
Volume
70,637
Avg. Vol
434,347
52-wk High
$21.12
52-wk Low
$10.80

Chart for

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $2,435.27
Shares Outstanding(Mil.): 141.92
Dividend: --
Yield (%): --

Financials

BRIEF-Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018

* HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018

10 Jan 2018

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

07 Dec 2017

BRIEF-Halozyme reports Q3 EPS of $0.02

* Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S

08 Nov 2017

BRIEF-Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex

* Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​

31 Oct 2017

Halozyme to license drug delivery tech to Roche, Bristol-Myers

U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

14 Sep 2017

BRIEF-Halozyme licenses new Enhanze target for $30 mln upfront payment

* Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties

14 Sep 2017

Halozyme to license drug delivery tech to Roche, Bristol-Myers

Sept 14 U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

14 Sep 2017

BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

* Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

14 Sep 2017

BRIEF-Halozyme reports Q2 loss per share $0.23

* Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

09 Aug 2017

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.352.10 +1.80
Sanofi SA (SASY.PA) €71.04 +0.21
Eli Lilly and Co (LLY.N) $85.39 -0.05
Albireo Pharma Inc (ALBO.OQ) $35.00 -0.39
MannKind Corporation (MNKD.OQ) $2.49 +0.04

Earnings vs. Estimates